- Home
- KALV vs ECX Comparison
KALV vs ECX Comparison
Compare KALV & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- ECX
- Stock Information
- Founded
- KALV N/A
- ECX 2017
- Country
- KALV United States
- ECX China
- Employees
- KALV N/A
- ECX N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- ECX EDP Services
- Sector
- KALV Health Care
- ECX Technology
- Exchange
- KALV Nasdaq
- ECX Nasdaq
- Market Cap
- KALV 523.1M
- ECX 584.9M
- IPO Year
- KALV N/A
- ECX N/A
- Fundamental
- Price
- KALV $11.18
- ECX $1.83
- Analyst Decision
- KALV Strong Buy
- ECX
- Analyst Count
- KALV 4
- ECX 0
- Target Price
- KALV $29.00
- ECX N/A
- AVG Volume (30 Days)
- KALV 247.5K
- ECX 25.1K
- Earning Date
- KALV 12-05-2024
- ECX 11-07-2024
- Dividend Yield
- KALV N/A
- ECX N/A
- EPS Growth
- KALV N/A
- ECX N/A
- EPS
- KALV N/A
- ECX N/A
- Revenue
- KALV N/A
- ECX $778,608,168.00
- Revenue This Year
- KALV N/A
- ECX N/A
- Revenue Next Year
- KALV $539.64
- ECX $39.50
- P/E Ratio
- KALV N/A
- ECX N/A
- Revenue Growth
- KALV N/A
- ECX 25.70
- 52 Week Low
- KALV $7.21
- ECX $0.96
- 52 Week High
- KALV $16.88
- ECX $4.07
- Technical
- Relative Strength Index (RSI)
- KALV 46.78
- ECX 51.03
- Support Level
- KALV $10.78
- ECX $1.72
- Resistance Level
- KALV $12.12
- ECX $1.86
- Average True Range (ATR)
- KALV 0.72
- ECX 0.07
- MACD
- KALV -0.07
- ECX 0.00
- Stochastic Oscillator
- KALV 41.20
- ECX 70.96
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services primarily in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.